BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Focosi D, Franchini M. Clinical predictors of SARS-CoV-2 neutralizing antibody titers in COVID-19 convalescents: Implications for convalescent plasma donor recruitment. Eur J Haematol 2021;107:24-8. [PMID: 33780551 DOI: 10.1111/ejh.13630] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Focosi D, Franchini M, Joyner MJ, Casadevall A, Sullivan DJ. Analysis of anti-Omicron neutralizing antibody titers in different convalescent plasma sources. medRxiv 2022:2021. [PMID: 35982681 DOI: 10.1101/2021.12.24.21268317] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
2 Schmidt AE, Vogel P, Chastain CA, Barnes T, Roth NJ, Simon TL. Analysis of 52 240 source plasma donors of convalescent COVID-19 plasma: Sex, ethnicity, and age association with initial antibody levels and rate of dissipation. J Clin Apher 2022. [PMID: 35815776 DOI: 10.1002/jca.21998] [Reference Citation Analysis]
3 Franchini M, Mengoli C, Ballotari A, Glingani C. Correlation between ABO blood group and neutralizing anti-SARS-CoV-2 antibody titers in convalescent plasma donations. Transfus Clin Biol 2021:S1246-7820(21)00478-X. [PMID: 34690072 DOI: 10.1016/j.tracli.2021.10.002] [Reference Citation Analysis]
4 Pang NY, Pang AS, Chow VT, Wang DY. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice. Mil Med Res 2021;8:47. [PMID: 34465396 DOI: 10.1186/s40779-021-00342-3] [Cited by in F6Publishing: 25] [Reference Citation Analysis]
5 Markmann AJ, Giallourou N, Bhowmik DR, Hou YJ, Lerner A, Martinez DR, Premkumar L, Root H, van Duin D, Napravnik S, Graham SD, Guerra Q, Raut R, Petropoulos CJ, Wrin T, Cornaby C, Schmitz J, Kuruc J, Weiss S, Park Y, Baric R, de Silva AM, Margolis DM, Bartelt LA. Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals. mSphere 2021;6:e0027521. [PMID: 34431693 DOI: 10.1128/mSphere.00275-21] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Focosi D, Franchini M, Pirofski LA, Burnouf T, Fairweather D, Joyner MJ, Casadevall A. COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors. Viruses 2021;13:1594. [PMID: 34452459 DOI: 10.3390/v13081594] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 de Candia P, Prattichizzo F, Garavelli S, La Grotta R, De Rosa A, Pontarelli A, Parrella R, Ceriello A, Matarese G. Effect of time and titer in convalescent plasma therapy for COVID-19. iScience 2021;24:102898. [PMID: 34316549 DOI: 10.1016/j.isci.2021.102898] [Reference Citation Analysis]
8 Focosi D, Franchini M. Clinical predictors of SARS-CoV-2 neutralizing antibody titers in COVID-19 convalescents: Implications for convalescent plasma donor recruitment. Eur J Haematol 2021;107:24-8. [PMID: 33780551 DOI: 10.1111/ejh.13630] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
9 Focosi D, Maggi F, Franchini M, Aguzzi A, Lanza M, Mazzoni A, Menichetti F. Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor-recipient differences in concentration of neutralizing antibodies. Clin Microbiol Infect 2021;27:987-92. [PMID: 33878505 DOI: 10.1016/j.cmi.2021.04.003] [Reference Citation Analysis]